Baillie Gifford & Co
JUNO

Baillie Gifford & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

Baillie Gifford & Co’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,547,788
Closed -$482M – 207
2017
Q4 		$482M Sell
10,547,788
-300,612
-3% -$15M 0.6% 38
2017
Q3 		$487M Sell
10,848,400
-324,729
-3% -$11.1M 0.62% 36
2017
Q2 		$334M Sell
11,173,129
-24,734
-0.2% -$610K 0.45% 54
2017
Q1 		$248M Buy
11,197,863
+135,908
+1% +$2.92M 0.36% 61
2016
Q4 		$209M Buy
11,061,955
+213,104
+2% +$5.21M 0.34% 64
2016
Q3 		$326M Buy
10,848,851
+5,179
+0% +$161K 0.51% 50
2016
Q2 		$417M Sell
10,843,672
-74,705
-0.7% -$3.1M 0.74% 40
2016
Q1 		$416M Buy
10,918,377
+10,638,377
+3,799% +$371M 0.73% 36
2015
Q4 		$12.3M Buy
+280,000
New +$13.9M 0.02% 134

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Baillie Gifford & Co's JUNO Position: Q1 2018 in Review

Baillie Gifford & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 10,547,788 shares — an estimated $482M sold.

Baillie Gifford & Co first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $487M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Baillie Gifford & Co reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Baillie Gifford & Co sold 10,547,788 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $482M.
  • Baillie Gifford & Co first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
  • Baillie Gifford & Co's Juno Therapeutics, Inc. position peaked at $487M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Baillie Gifford & Co's 13F filing for Q1 2018, filed 10 May 2018.